Fractyl Health reports positive 6-month results from its REVEAL-1 Cohort study on post-GLP-1 weight maintenance.
Participants who lost 24% total body weight on GLP-1 drugs maintained stable weight 6 months after discontinuation and a single Revita procedure.
New data highlights Revita's potential as a pioneering therapy for post-GLP-1 weight maintenance.
Sustained Weight Maintenance
Participants maintained stable weight with a mean total body weight change of 1.5% after a single Revita procedure.
Sustained Glycemic Control
Minimal change in HbA1c levels post-Revita, indicating potential for stabilizing cardiometabolic parameters.
Stable Metabolic Trajectory
Consistent body weight and HbA1c trajectories over 1, 3, and 6 months suggest durable metabolic control with Revita.
Excellent Tolerability
No serious adverse events related to the procedure, with mild transient events observed in a small percentage of participants.
Reproducible Procedure Performance
Ablation length consistent with prior experience, supporting potential scalability and translation of results.
- The results demonstrate a potential off-ramp from GLP-1 drugs for patients seeking long-term metabolic health.
- Revita's positive outcomes offer a new strategy for weight and metabolic maintenance post-GLP-1 therapy discontinuation.
The REVEAL-1 study outcomes signify a significant advancement in understanding the efficacy of Revita for sustained weight and metabolic control post-GLP-1 therapy. Fractyl Health's dedication to innovative approaches in obesity and diabetes treatment is evident in these promising results.